LAB/B: Q2 2024 delivered strong profit growth, margin expansion, and strategic M&A activity

About this update from Genomma Lab Internacional Sab De Cv Class B

Q2 2024 saw robust profitability and margin expansion, with net income up 50.1% and EPS up 53.1% year-over-year. Strategic M&A, productivity gains, and strong segment performance in Mexico and the U.S. offset macro headwinds and FX volatility. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genomma Lab Internacional Sab De Cv Class B